Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
0 hedge funds and large institutions have $0 invested in Acorda Therapeutics in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $8K → $0 (-$8K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| – | -$8K | -33,691 | Closed |
|
ACOR Hedge Fund Activity: Q3 2024 in Review
0 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2024, worth a combined $0 — down 100% from $8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ACOR and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Acadian Asset Management, exiting entirely with an estimated $8K sold.
- 0 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2024, down from 2 in Q2 2024.
- Funds reported $0 of Acorda Therapeutics stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new Acorda Therapeutics positions in Q3 2024 and 2 closed out, a net change of -2 holders.
- The largest Acorda Therapeutics seller in Q3 2024 was Acadian Asset Management, an estimated $8K sold.
Based on aggregated 13F filings for Q3 2024.